Molecular Partners (MOLN) TD Cowen 45th Annual Healthcare Conference summary

Strategic focus and technology overview

• Emphasis on developing DARPins, small proteins engineered for high specificity and deep tissue penetration, targeting high medical need indications.

• Two main development areas: T-cell engagement (immunotherapy) and a rapidly expanding radiopharma pipeline.

• Seven DARPins are currently in clinical development, providing significant learning about the modality.

• The next 12–18 months are expected to be pivotal for progress and data readouts.

Radiopharma platform and partnerships

• Radio DARPin platform leverages small size, high affinity, and engineered fast kidney clearance for improved tumor targeting.

• Lead clinical candidate targets DLL3 in small cell lung cancer, aiming to address significant unmet medical need.

• Partnership with Orano Med secures access to Pb-212, an alpha-emitting isotope, with Sanofi investing $400M to strengthen supply chain.

• Clinical entry for lead candidate MP0712 is imminent, with phase zero/one studies set to begin within months.

• Updates on clinical progress are expected before year-end, with contingency plans for US and European execution.

Immune oncology and T-cell engager pipeline

• MP0533 is a tri/tetraspecific T-cell engager for AML, showing encouraging early safety and efficacy signals.

• Dose escalation and schedule optimization are ongoing to maximize early and durable responses.

• Target efficacy bar is a response rate above 30% and durability of 5–6 months in a broad patient population.

• Safety profile is favorable, with manageable immune-related adverse events and a broader therapeutic window than comparable agents.

• Strong collaboration with leading clinical sites and expert advisors is guiding protocol development and patient selection.